Menu
Search
|

Menu

Close
X

Tenax Therapeutics Inc TENX.OQ (NASDAQ Stock Exchange Capital Market)

4.79 USD
-0.11 (-2.24%)
As of Oct 19
chart
Previous Close 4.90
Open 5.00
Volume 854
3m Avg Volume 2,065
Today’s High 5.00
Today’s Low 4.76
52 Week High 12.59
52 Week Low 4.42
Shares Outstanding (mil) 1.47
Market Capitalization (mil) 7.68
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-2.117
FY17
-6.269
FY16
-31.240
FY15
-10.252
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
--
6.55
Price to Book (MRQ)
vs sector
1.22
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.00
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-64.34
12.83
Return on Equity (TTM)
vs sector
-64.34
14.95

EXECUTIVE LEADERSHIP

Ronald Blanck
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Michael Jebsen
President, Chief Financial Officer, Since 2018
Salary: $285,000.00
Bonus: --
Anthony DiTonno
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Douglas Hay
Executive Vice President - Regulatory Affairs, Since 2013
Salary: --
Bonus: --
Doug Randall
Executive Vice President - Business and Commercial Operations, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Copley Pkwy Ste 490
MORRISVILLE   NC   27560-9693

Phone: +1919.8064414

Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

SPONSORED STORIES